1 TITLE

2 Gene signatures and host-parasite interactions revealed by dual single-cell profiling of *Plasmodium vivax*

3 liver infection

4

5

6

7

8 AUTHORS

9 Liliana Mancio-Silva[1, 2, 3, 10], Nil Gural[1, 2, 10], Marc H. Wadsworth II[1, 4], Vincent L. Butty[2, 5], Travis K.

10 Hughes[1, 4], Sandra March[1, 2], Niketa Nerurkar[1, 2], Wanlapa Roobsoong[6], Heather E. Fleming[1, 2], Charlie

11 Whittaker[2, 5], Stuart S. Levine[2, 5], Jetsumon Sattabongkot[6], Alex K. Shalek[1, 2, 4, 7, 8, *], Sangeeta N. Bhatia[1, 2,

12 8, 9, *]

13

14 [1] Institute for Medical Engineering and Science, MIT, Cambridge, MA, 02142 USA

15 [2] David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, 02142 USA

16 [3] Institut National de la Santé et de la Recherche Médicale, Unité 1201, Paris, France

17 [4] Department of Chemistry, MIT, Cambridge, MA 02142, USA

18 [5] BioMicro Center, MIT, Cambridge, MA 02142, USA

19 [6] Mahidol Vivax Research Unit, Faculty of Tropical Medicine Mahidol University, Bangkok 10400,

20 Thailand

21 [7] Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02142, USA

22 [8] Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

23 [9] Howard Hughes Medical Institute, Chevy Chase, MD, 20815 USA

24 [10] equal contributions

25

26 * Correspondence: shalek@mit.edu, sbhatia@mit.edu

27

28

29

30 SUMMARY

31 Malaria-causing *P. vivax* parasites can linger in the human liver for weeks to years, and then reactivate to

32 cause recurrent blood-stage infection. While an important target for malaria eradication, little is known

33 about the molecular features of the replicative and non-replicative states of intracellular *P. vivax* parasites,

34 or the human host-cell responses to them. Here, we leverage a bioengineered human microliver platform to

35 culture Thai clinical isolates of *P. vivax* in primary human hepatocytes and conduct transcriptional profiling

36 of infected cultures. By coupling enrichment strategies with bulk and single-cell analyses, we captured both

37 parasite and host transcripts in individual hepatocytes throughout the infection course. We defined host-

38 and state-dependent transcriptional signatures and identified previously unappreciated populations of

39 replicative and non-replicative parasites, sharing features with sexual transmissive forms. We found that

40 infection suppresses transcription of key hepatocyte function genes, and that *P. vivax* elicits an innate

41 immune response that can be manipulated to control infection. Our work provides an extendible framework

42 and resource for understanding host-parasite interactions and reveals new insights into the biology of

43 malaria dormancy and transmission.

44

45

46 KEYWORDS

47 *Plasmodium vivax*, hypnozoites, dormancy, hepatocytes, single-cell, transcriptomics, host-parasite

48 interactions

49

INTRODUCTION

Plasmodium parasite, the causative pathogen of malaria, has a complex life cycle that spans multiple hosts. Disease transmission is initiated upon bite of an infected *Anopheles* mosquito, which deposits infective parasites, called sporozoites, into the human host. Sporozoites travel to the liver, invade hepatocytes and replicate, forming thousands of new parasites called merozoites, which eventually break out into the blood stream, cyclically invading erythrocytes and initiating clinical symptoms. Parasite transmission back to the mosquito is ensured by the development of sexual gametocyte forms during the asexual erythrocytic cycle that are taken up upon bite to restart the life cycle in the insect host. Uniquely, in the case of *P. vivax*, a subset of liver-stage parasites develops into dormant forms called hypnozoites, which can re-activate weeks to years after initial infection to cause relapsing disease. Thus, the liver-stage, which is obligate yet clinically silent and includes relapse-causing hypnozoites, presents a unique opportunity for malaria intervention before onset of symptoms. However, our knowledge of liver-stage malaria, and the response of its hepatocyte host is sparse due to difficult access to the parasite and lack of suitable human liver models. To date, much of our historical knowledge has been based on liver biopsies of infected patients, making it challenging to perform mechanistic studies on liver-stage forms, especially the quiescent hypnozoites. Transcriptomic studies hold promise for unveiling mechanistic insight into liver-stage *P. vivax* relapsing biology, but the low infection rate and the reduced quantity of parasite transcripts in a transcriptionally active host cell environment has made it difficult to perform these studies.

We recently provided some of the first insights into the transcriptional features of *P. vivax* liver-stages by leveraging an *in vitro* primary human liver platform (MPCC, micropatterned co-cultures) that recapitulates key aspects of *P. vivax* liver-stage biology, including establishment of persistent dormant forms, growing schizonts, merozoite release, and subsequent infection of overlaid erythrocytes. Our work revealed reduced transcriptional activity in hypnozoite-enriched samples, specifically, suppressed transcripts for functions related to cell division and invasion machinery, consistent with a quiescent state (Gural et al., 2018). However, the single time-point bulk sequencing used in this study prevented us to capture the inherent heterogeneity of the distinct liver-stage parasite forms. Achieving a deeper understanding of pathogen-host interactions has the potential to provide insight into mechanisms that could be leveraged to treat or prevent infection, as suggested by innate interferon responses to infection by rodent malaria parasites (Liehl et al., 2013) and a number of viruses (Schneider et al., 2014). However, a closer look into infection-specific host responses and potential protective responses in uninfected neighbors requires single-cell resolution. Recently, diverse single-cell technologies have revealed stage-specific transcriptional signatures in mosquito (Real et al., 2021), blood and gametocyte (Poran et al., 2017; Walzer et al., 2018) stages from non-relapsing human parasites, and the entire life cycle of rodent parasites (Howick et al., 2019), all of which can be easily cultured and propagated in laboratories. For *P. vivax*, single-cell transcriptomic studies have been conducted in blood-stages collected from infected monkeys (Sà et al., 2020), but analysis of liver infection has not been performed to date.

Here, we present the first comprehensive view of the liver-stage transcriptomes of a human-infecting malaria parasite and its host cells at single-cell resolution. To achieve this goal, we coupled MPCC with Seq-Well, a recently developed low-cost and portable single-cell platform that does not require fluorescent labeling and is compatible with use of samples collected in endemic settings (Gierahn et al., 2017; Hughes et al., 2020). With this combined platform, we define distinct signatures between early, dormant, mid, and late-stage parasites, and identify a sub-population of sexually committed forms in the liver, previously thought to appear only during erythrocytic infection. We interrogate pathogen-host interactions and describe innate immune responses by uninfected bystander cells, representing a likely mechanism for endogenous protection from secondary infections. We validate expression of host candidates and report cytokine- and stage-dependent anti-parasite activity by induction of interferon signaling. Together, the data presented here provide a closer look at transcriptional signatures in *P. vivax* liver-stages, including host responses, and offer novel insights into their unique biology.

100   RESULTS
101
102   **Profiling liver-stage *P. vivax* infection by pairing targeted sequencing with single-cell analysis**
103   To comprehensively profile *P. vivax* liver-stage infection, we collected cells from MPCC cultures of
104   primary human hepatocytes at multiple time points following infection (**Figures 1A-B, S1A**). Sampling
105   spanned the full liver-stage developmental period (days 1 to 11), comprising a mix of both replicating
106   schizonts and non-replicative hypnozoites. To obtain hypnozoite-enriched samples, MPCCs were treated
107   from day 5 to 8 with a phosphatidylinositol 4-kinase (Pi4K) inhibitor compound, a dosing regimen that
108   eliminates the replicative parasites while preserving the dormant parasites (Gural et al., 2018). For
109   hypnozoite-enrichment without drug treatment, we collected cultures at day 14. To obtain a baseline
110   reading of the host response, naïve and mock-exposed MPCCs were prepared and collected in parallel. A
111   total of 56 samples from two independent infections performed with clinical Thai *P. vivax* isolates were
112   processed for high throughput single-cell RNA sequencing (scRNA-seq) using Seq-Well S[3] (Hughes et al.,
113   2020). Samples were also collected in bulk for RNA sequencing (RNA-seq) analysis (**Figure 1A**).
114   Because whole transcriptome scRNA-seq resulted in poor representation of *P. vivax* genes and
115   transcripts, we incorporated an additional step whereby barcoded parasite transcripts were enriched using
116   previously validated nucleic acid baits targeting the entire *P. vivax* genome (Gural et al., 2018). Capture
117   and re-sequencing of samples increased the efficiency of *P. vivax* gene and transcript detection by 5.6-fold
118   per single parasite (**Figures 1C, S1B**). Combining single-cell transcriptomes from pre- and post-capture,
119   we recovered 1,991 individual parasites with greater than 10 genes or 100 *P. vivax*-mapped transcripts. This
120   tally fairly reflects the number of hepatic infections at the different timepoints, except for day 11 samples
121   from which a higher number of parasites was recovered (likely representing free merozoites released from
122   mature schizonts during sample processing; **Figure S1A; Table S1**).
123
124   **Single-cell profiling *P. vivax* liver infection defines stage-specific gene signatures**
125   Integration of parasite transcriptomes with Scanorama yielded 8 *P. vivax* clusters, corresponding to distinct
126   developmental liver-stages that were visualized by uniform manifold approximation and projection
127   (UMAP; **Figures 1D-E**). Cluster Pv_C1 contains early-stage individual parasites (day 1), while clusters
128   Pv_C2-C4 comprise *P. vivax* parasites present in the mixed samples collected on days 4 to 8, as well the
129   hypnozoites from Pi4K-enriched cultures and the day 14 samples. Late-stage schizont parasites (day 11) are
130   scattered across clusters Pv_C5-C8.
131   Based on the gene patterns that define each cluster (**Figure S2A; Table S1**), early liver-stage
132   parasites (Pv_C1) are characterized by residual expression of sporozoite-specific genes and expression of
133   genes involved in cytoskeleton organization process, likely necessary to establish intracellular infection.
134   Pv_C2-C4 clusters appear to represent a core mid-stage liver program, comprising genes implicated in
135   housekeeping functions important for parasite growth such as translation (*EIF1D,G; EIF2A,B; EIF3A-E*)
136   and metabolism (*ENO, ACC, HCS1*). Well-characterized genes such as those encoding liver-specific
137   protein 1 (*LISP1*) and 2 (*LISP2*) appear as top marker genes for these clusters. Progressing along the liver-
138   stage development, GO terms for cell cycle, mitotic division, and adhesion of symbiont to host become
139   significantly represented in Pv_C5-C6. Gene cluster identifiers include several members of merozoite
140   surface proteins (*MSP*), serine repeat antigen (*SERA*), rhoptry associated (*RAP, RAMA*) and rhoptry neck
141   (*RON*) multigene families that are necessary for red blood cell invasion, and also the merozoite egress
142   subtilisin-like protease 1 (*SUB1*). Finally, among the late-stage parasites Pv_C7-C8 represent a previously
143   unidentified population of hepatic parasites that co-express merozoite- and gametocyte-specific genes.
144   Marker genes for these clusters include multiple copies of the tryptophan-rich protein family, which are
145   expressed by merozoites of multiple *Plasmodium* species and have been implicated in erythrocyte invasion,
146   the gametocyte antigen *G27/25,* the gamete release protein (*GAMER*) and the homolog of gametocyte
147   exported protein 5 (*GEXP5*, aka *PHISTc*).
148

3

Transcriptional profiling of *P. vivax* liver-stages reveals early sexual commitment

To gain further insight into the subpopulation of parasites defined by clusters Pv_C7 and Pv_C8, we searched the dataset for additional gametocyte-specific genes. Expression of canonical sexual markers (*PVS16, P28, P230),* including male (*MGET* and *MDG1*) and female (*RUBV1* and *G377*) specific genes recently assigned to *P. vivax* (Sà et al., 2020), was detected throughout the developmental liver-stages in multiple clusters (**Figure 2A**). Their expression was also confirmed via targeted bulk RNA-seq (**Figure 2B; Table S2**) and by RT-qPCR analysis of a small subset of genes (**Figure 2C**). For further validation, we performed *in situ* hybridization for *GEXP5*, which appears highly expressed in day 11 samples (**Figures 2B, 2C**) and is known as an early sexual stage marker in blood-stages of the human malaria parasite *P. falciparum* (Tibúrcio et al., 2015). We found *GEXP5* transcripts in 5-15% of schizonts, with positive signal in all merozoites, while the remaining schizonts did not contain this transcript (**Figure 2D**). Interestingly, we found that 16-25% of parasites in clusters Pv_C1 and Pv_C6 (**Figure 2A; Table S1**) express the gene encoding AP2-G, the transcriptional master regulator of sexual development in blood stages (Kafsack et al., 2014; Sinha et al., 2014). Exploring the dynamics of this transcription factor, we found induced expression of *AP2-G* and its upstream activator, gametocyte development 1 (*GDV1*) (Filarsky et al., 2018), as early as day 1 after hepatocyte invasion. Expression of *PVS16*, a downstream target of AP2-G increased from day 2, and onwards (**Figure 2E**). PVS16 protein has been detected in a fraction of *P. vivax* hepatic schizonts at day 8 (Roth et al., 2018; Schafer et al., 2020). Altogether, the data indicates that commitment to gametocytogenesis might occur early during liver-stage development in a subset of parasites, likely leading to formation of sexually committed merozoites.

P. vivax non-replicative liver-stages depend on proteolytic activity and are sexually committed

To inform the identification of hypnozoite-specific gene signature(s), we re-clustered the mid-stage parasite clusters Pv_C2-C4 (**Figures 3A-B; Table S1**). This enabled us to explore transcriptional differences among the mixed and hypnozoite-containing samples and revealed a sub-cluster (Pv_SC3) significantly enriched in genes encoding proteins with peptidase activity (10 genes) and nucleic acid binding proprieties (18 genes) in the non-replicative parasite population. These include several members of protease families (vivapains and plasmepsins), members of ApiAP2 family of transcription factors (*AP2-Tel* and *AP2-FG*) and *PUF1,* a Pumilio RNA binding protein known to be involved in translational repression (Bennink and Pradel, 2019). Consistent with a quiescent state, parasites in Pv_SC3 show low levels of the replicative marker *LISP2* (**Figure 3C**). The expression of transcriptional regulators of gametocytogenesis *AP2-G* and *AP2-FG* prompted us to look for additional gametocyte-related genes (as in **Figure 2A**). Remarkably, we found expression of canonical sexual markers (*P28, P25, P230*) in Pv_SC3 subcluster, suggesting that a subpopulation of *P. vivax* quiescent hypnozoites could be pre-committed to become sexually transmissive forms (**Figures 3C-D**). A larger number of gametocyte-specific genes however was found in the Pv_SC5 subcluster, which is largely *LISP2* positive. Thus, Pi4K-treated and day 14 parasites in Pv_SC5 subcluster likely represent a subpopulation of sexually committed reactivating hypnozoites. Presence of gametocyte-specific transcripts in Pi4K-treated samples was confirmed by RT-qPCR analysis, further supporting the concept that non-replicative parasites could be sexually committed (**Figure S3A**).

Protein degradation is important for maintenance of a hibernatory state induced by nutrient limitation during the *P. falciparum* erythrocytic cycle (Babbitt et al., 2012). To determine whether proteolytic activity could be required to maintain viability of quiescent hypnozoites, we exposed *P. vivax*-infected MPCCs to E64, a membrane-permeable protease inhibitor. No effect was found on schizont forms, however, the number of *P. vivax* hypnozoites was significantly reduced in the E64-treated cultures (**Figures 3E, S3B**). Altogether the results suggest that *P. vivax* hypnozoites in the liver could represent a reservoir of sexually committed parasites and dormancy might depend on transcription and translational repression mechanisms and proteolysis for long-lasting viability.

Pre-erythrocytic sexual differentiation is associated to distinct host metabolic states

To characterize host cell signatures linked to infection and host-dependent differences in parasite transcriptomes, we profiled samples of unexposed, mock- and *P. vivax*-exposed MPCCs across all timepoints. Integrating the data from 31,767 high-quality human transcriptomes with Seurat revealed 8 human clusters, likely representing diverse hepatic cell states (**Figures 4A, S4A**). Automated annotation of the clusters using SingleR tool identified clusters H0 to H3 as hepatocytes, exhibiting canonical markers of hepato-specific functions (**Figure S4B**). Albeit in small numbers, the remaining clusters H4 to H7 appear to include other cell types besides hepatocytes, such as endothelial and immune cells, likely present in the primary human liver sample used to generate the MPCC. Notably, the cells in the outlying cluster H8 express classical immune markers such as *CD45*, *CD4* and *CD32*.

P. vivax-associated hepatocytes were embedded throughout the cluster landscape, without a clear segregation between infected and non-infected cells (**Figure 4B**). Nevertheless, comparing *P. vivax*-positive and -negative cells in general demonstrated that infected cells are transcriptionally distinct (**Figures 4C, S4C; Table S3**). Gene set enrichment analysis revealed suppression of immune defense and liver-specific functions and increased expression of genes related to membrane organization and modulation by symbiont of host cellular process in *P. vivax*-infected cells (**Figure S4C**). Examples of differentially expressed genes include markers of inflammation and stress response, such as the family of acute-phase serum amyloid A proteins (*SAA4*) and the NFKB inhibitor alpha, caspases and apoptosis regulators (*BIRC3* and *IFI6*), and a glucose transporter (*SLC2A2*) with increased expression in the *P. vivax*-infected population. In contrast, interferon (IFN) regulatory factors (*IRF7*) and IFN induced proteins (*MX1*) are expressed at low levels in *P. vivax*-positive cells. Notably, *EPHA2* was found expressed in higher levels in 50% of the infected cells, consistent with a recent report identifying it as a host factor for human-infecting *P. falciparum* and rodent parasites (Kaushansky et al., 2015). Comparing infected hepatocytes that harbored mid- and late-stage parasites, we found IFN-related genes with significant increased expression in late infection, such as *ISG15*, *IFIT1* and *IFI6,* which might be involved in creating a permissive environment for parasite late-stage development and replication (**Figure 4D; Table S3**).

Given that sexual differentiation and gametocytogenesis in malaria parasites have been linked to host-derived physiological signals (Brancucci et al., 2017), we next compared the transcriptomes of hepatocytes hosting *P. vivax* parasites expressing the transcription factor *AP2-G* versus *AP2-G* negative. Interestingly, we found that hepatocytes bearing *AP2-G* positive parasites exhibit significant lower expression of genes encoding proteins implicated in intracellular iron storage (*FTL* and *FTH1*) and lipid metabolism (*APOA2, APOC1, APOC3, FABP1, CYP3A4*). Genes encoding albumin (*ALB* and *TTR*) and some mitochondrial proteins are also differentially expressed (**Figure 4E; Table S3**). These observations suggest that deficiency in specific intracellular metabolites (possibly iron or lipids) could serve as trigger for *AP2-G* induction and pre-erythrocytic sexual commitment.

Interferon responses in uninfected bystander hepatocytes

Taking advantage of our single-cell approach, we also investigated the impact of *P. vivax* infection in the neighbor hepatocytes. Comparing the transcriptomes of cells exposed to *P. vivax* to mock-exposed or naïve hepatocytes, we detected a widespread induction of the alpha/beta IFN response, mainly in the *P. vivax*-exposed uninfected cells (**Figures 4F-H**). Day 1 samples stand out given that the induction of multiple IFN-responsive genes and gene families, including *IRF7*, *IFI6*, *IFI27*, *IFIT1-5*, *IFI44* and *IFIH1* is observed in more than 40% of the hepatocytes (**Figure 4F**). Transcripts of effector IFN-induced transmembrane proteins *IFITM2* and *IFITM3* are increased throughout the infection time course (**Figure 4F**). The observed temporal order and gene composition of the IFN response to *P. vivax* is remarkably similar to that of hepatitis C virus (HCV) infection (Sheahan et al., 2014), suggesting a common hepatocyte defense mechanism in response to hepatotropic pathogens.

To validate our findings with an independent approach, we performed immunofluorescence analysis of IFITM3 in *P. vivax*-infected MPCCs at a late infection time-point. We found that IFITM3

245   protein localizes in the bile canaliculi and tight junctions and confirmed the upregulation of IFITM3 in the
246   uninfected bystander cells, with higher expression detected in the vicinity of infected hepatocytes (**Figures**
247   **5A-B**). IFITM3 has recently been shown to enhance the trafficking of virus particles to lysosomes (Spence
248   et al., 2019), and thus could be involved in targeting parasites for degradation. Based on its localization,
249   IFITM3 could also be involved in gap junction communication and propagation of host responses from
250   infected cells to uninfected neighbors (Luther et al., 2020; Patel et al., 2009).
251
252   **Host interferon responses control *P. vivax* infection**
253   Given the induced innate immune responses observed during early *P. vivax* infection, we hypothesized that
254   the activation of this pathway could be associated with the significant drop in parasite numbers observed
255   from day 1 to 11 (**Figure S1A**). To assess the impact of activated IFN signaling on the progression of *P.*
256   *vivax* infection in MPCCs, we treated infected cultures with IFN alpha (IFNa) and beta (IFNb) cytokines.
257   As control, we used IFN gamma (IFNg), which is known to reduce *P. vivax* infection (Boonhok et al.,
258   2016; Ferreira et al., 1986). While no effect was detected in terms of the kinetics or frequency of parasite
259   development (**Figure S5**), the number of both *P. vivax* schizonts and hypnozoites were significantly
260   reduced upon treatment with IFNa (**Figure 5C**). IFNb appeared to have a stronger effect on schizont stages,
261   by contrast IFNg treatment revealed a potent anti-hypnozoite activity, which is shown here for the first
262   time. Altogether, the results suggest that successful *P. vivax* infection likely involves robust mechanisms
263   for subverting host IFNa/b responses, which might be long-lasting in the hepatocytes that harbor dormant
264   hypnozoites.
265
266
267   DISCUSSION
268
269   Here we comprehensively surveyed the molecular composition of *P. vivax* parasites in distinct liver-stages,
270   as well as their host or neighboring hepatocytes, throughout the course of infection, providing the first
271   single-cell liver atlas of relapsing human malaria. Leveraging the portability of two established platforms
272   (MPCC and Seq-Well) to culture and collect individual human hepatocytes infected in an endemic location,
273   we performed dual single-cell sequencing analysis and further developed a method to selectively enhance
274   capture of parasite transcripts. We demonstrated the robustness and utility of this approach by sequencing
275   1,991 *P. vivax* parasites and 31,767 hepatocyte transcriptomes and provided validations and mechanistic
276   insights for newly identified gene signatures and parasite-host interactions.
277   Dual transcriptional profiling of *P. vivax* infection revealed host- and stage-dependent gene
278   expression patterns in both parasites and hepatocytes. Our data is consistent with the following model: upon
279   invasion, a subset of *P. vivax* sporozoites in cells with reduced hepatic metabolism in will activate *AP2-G*.
280   Of those, a fraction will remain dormant, while the remaining portion will activate the schizogony program.
281   Thus, at the point of egress, two populations of hepatic *P. vivax* merozoites will emerge from the liver: the
282   asexual population developing into blood-stages, and the sexually committed population developing into
283   gametocytes for mosquito transmission. This model, while distinct from the existing understanding of the
284   *Plasmodium* life cycle, is in agreement with historical observations of rapid *P. vivax* transmission that
285   occur before the onset of symptoms (Baker, 2010), and is consistent with the high abundance of gametocyte
286   transcripts detected in blood collected from malaria patients (Adapa et al., 2019; Kim et al., 2019). In our
287   model, parasites that do not activate schizogony, the hypnozoites, remain in a dormant state via
288   transcriptional/translational repression mechanisms and rely on proteolytic activity to sustain viability.
289   Bypassing the need for an asexual replication phase might represent an evolutionary imperative to preserve
290   genome integrity, given the prolonged period between infection and transmission. From a clinical
291   perspective, this model would advocate for the development of a novel "wake and kill" clinical approach;
292   namely, to leverage drugs that enhance gametocyte commitment as a way to reduce the hypnozoite
293   reservoir in the liver. Parasite-specific protease inhibitors could also be screened for anti-relapsing activity.

294   Additionally, our work reveals dysregulation of IFN and inflammatory signaling pathways in *P.*
295 *vivax*-infected hepatocytes. The reduced expression of IFN-responsive genes in infected cells suggests a
296 protection mechanism for the parasite from host cell-mediated killing. In fact, induction treatments with
297 IFN in our immune-cell free microliver system demonstrated anti-parasite activity against both schizonts
298 and hypnozoites. Downregulation of IFN signaling may also contribute to under-activation of adaptative
299 immune responses by antigen presenting cells, leading to parasite persistence in the organism. However,
300 the mechanisms by which IFN suppression is achieved in infected cells or the impact of host genetics and
301 host-dependent IFN responses, key determinants of clinical outcome in HCV infections (Sheahan et al.,
302 2014), remain unknown. In contrast, we described upregulation of innate immune response pathways in
303 uninfected bystander cells, similar to those observed in viral infections that help control spreading of the
304 virus to neighboring cells (Kotliar et al., 2020; Sheahan et al., 2014). In the context of malaria, this
305 phenomenon might prime or protect cells from a secondary infection, as suggested by the inhibition of
306 malaria re-infection by IFN in a rodent model of *Plasmodium* (Liehl et al., 2013, 2015). Future studies
307 employing spatial single-cell transcriptomics could reveal *P. vivax*-specific gene signatures and spatially
308 heterogeneous responses in bystander cells.

309   In summary, this study presents the first transcriptional description of individual *P. vivax* liver-
310 stages, their host cells and uninfected bystander cells over the course of infection in human hepatocytes.
311 Leveraging multiple single-cell technologies (sequencing, *in situ* hybridization, and immunofluorescence),
312 we reveal earlier-than expected sexual commitment during *P. vivax* liver-stage development in both
313 replicative and non-replicative parasites, and a dominant innate immune response that exhibits distinct
314 signatures in infected and uninfected bystander hepatocytes. Taken together, these clinically relevant
315 insights provide a framework for characterizing host-parasite interactions in *P. vivax* infections. We expect
316 the methods described here to be applicable for profiling not only other *Plasmodium* parasites at various
317 stages of the life cycle, but also other intracellular pathogens where low abundance of transcripts or host
318 contamination make it difficult to perform single-cell studies.

319
320
321

328   MATERIALS & METHODS
329
330   **Fibroblasts and primary cell cultures**
331   J2-3T3 male murine embryonic fibroblasts (gift of Howard Green, Harvard Medical School) were cultured
332   at < 20 passages in medium comprising of Dulbecco's Modified Eagle Medium (DMEM, Corning), 10%
333   (v/v) bovine serum (Thermo Fisher Scientific), and 100 mg/mL penicillin-streptomycin (Corning) and were
334   kept at 37°C in a 5% CO2 environment.
335   Cryopreserved primary human hepatocytes were purchased from BioIVT, a vendor permitted to sell
336   products derived from human organs procured in the United States of America by federally designated
337   Organ Procurement Organizations. Human hepatocytes (male donor, age 57) were maintained in DMEM
338   with 10% fetal bovine serum (FBS, GIBCO), 1% ITS (insulin/transferrin/selenous acid and linoleic acid,
339   BD Biosciences), 7 ng/mL glucagon (Sigma-Aldrich), 40 ng/mL dexamethasone (Sigma-Aldrich), 15 mM
340   HEPES (GIBCO), and 100 mg/mL penicillin-streptomycin (Corning). Hepatocyte cultures were kept at
341   37°C in a 5% CO2 environment.
342
343   *P. vivax* parasites
344   *Anopheles dirus* mosquitoes were fed on blood collected from symptomatic patients attending malaria
345   clinics in Tak, Songkla, and Ubon-Ratchathani Provinces in Thailand, confirmed positive for only *P. vivax*
346   via microscopy and RT-PCR. Briefly, *P. vivax* infected blood was drawn into heparinized tubes and kept at
347   37°C until processing. Infected blood was washed once with RPMI 1640 incomplete medium. Packed
348   infected blood was resuspended in warm non-heat inactivated naive human AB serum for a final hematocrit
349   of 50%. Resuspended blood was fed to laboratory reared female *Anopheles dirus* mosquitoes for 30
350   minutes via an artificial membrane attached to a water-jacketed glass feeder kept at 37°C. Engorged
351   mosquitoes were kept on 10% sugar at 26°C under 80% humidity at the designated insectary at the Mahidol
352   Vivax Research Unit. Sporozoites were dissected from the salivary glands of infected mosquitoes 14-21
353   days after blood feeding and pooled in DMEM supplemented with 200 mg/mL penicillin-streptomycin.
354
355   **MPCCs and *P. vivax* infection**
356   Primary human hepatocytes were seeded on collagen-micropatterned 96-well plates and surrounded with
357   murine embryonic fibroblasts 3T3-J2s as detailed previously (March et al., 2015). For the scRNA-seq
358   analysis, MPCCs were established using 3T3-J2s expressing an inducible apoptosis switch (Chen et al.,
359   2020). MPCCs were infected with fresh sporozoites obtained through dissection of *P. vivax*-infected
360   mosquitoes. For mock samples, MPCCs were exposed to material from non-infected mosquito salivary
361   glands (matched number of dissected mosquitoes). Unexposed samples received the vehicle. For scRNA-
362   seq, *P. vivax*-infected cultures were collected from duplicate wells, whereas mock and unexposed samples
363   represent single wells for each time-point. For IFN treatments, MPCCs were infected in triplicate wells.
364
365   **Drug treatments**
366   To obtain hypnozoite-enriched samples, *P. vivax*-infected MPCCs were dosed with a schizont-specific drug
367   Pi4K inhibitor (MMV390048, 1 μM) for 3 days starting on day 5 after infection. Similar dosing schedule
368   was used for treatments with IFN alpha 2a (11100-1), beta (8499-IF-010) and gamma (285-IF-100) (all
369   purchased from R&D Systems). Cytokine units tested are given in the figures. E64 treatment started at 4h
370   post-infection after media washing the cultures.
371
372   **Seq-Well and hybrid capture**
373   For the scRNA-seq analysis, an updated Seq-Well protocol including a second-strand synthesis step was
374   employed (Hughes et al., 2020). Briefly, MPCCs were first treated with AP20187 (0.5 μM) for 30 minutes
375   at 37°C to partially deplete the fibroblast cells via apoptosis. After washing, the cultures were dissociated
376   by Trypsin (0.25%) 5-minute treatment at 37°C. A suspension with 10-15,000 cells was then loaded onto a

377 functionalized-polydimethylsiloxane array preloaded with uniquely barcoded mRNA capture beads. After
378 cells had settled into wells, the array was sealed with a hydroxylated polycarbonate membrane with a pore
379 size of 10 nm, facilitating buffer exchange while permitting cell lysis, mRNA transcript hybridization to
380 beads, and bead removal before proceeding with reverse transcription. The obtained bead-bound cDNA
381 product then underwent Exonuclease I treatment to remove excess primer before proceeding with second-
382 strand synthesis and PCR amplification.
383 To capture parasite reads from Seq-Well, full length cDNAs were amplified an additional 5 cycles using
384 Kapa HiFi polymerase including a 3-minute extension time to increase concentration for capture. 200-300
385 ng of cDNA was concentrated using a speedvac, reconstituted in 3.4 μL water and hybridized for 32 hours
386 as previously described (Gural et al., 2018). 10 μL of capture material was amplified for 15 cycles
387 following the standard protocol. Captured cDNA was then prepared into Illumina libraries using
388 NexteraXT (Illumina). Final libraries were quality controlled using Fragment Analyzer (Agilent) and qPCR
389 prior to Illumina sequencing (NextSeq500).
390
391 **Quantitative RT-PCR**
392 Total RNA from pooled triplicate wells of *P. vivax*-infected MPCCs was extracted with TRIzol (Thermo
393 Fisher), DNAse treated and purified using the RNeasy MinElute Cleanup Kit (Qiagen). cDNA synthesis
394 was performed using SuperScript II (Thermo Fisher) and RT-PCR was carried out using PowerUp SYBR
395 Green Master Mix (Applied Biosystems) in a Roche Light Cycler 480 Real-Time PCR Detection System
396 according to the manufacturer's instructions. The primers used are listed in **Table S4**. Relative gene
397 expression was calculated with the delta-delta Ct method, using PVP01_1213400 as housekeeping gene.
398
399 **Immunofluorescence analysis**
400 *P. vivax*-infected MPCCs were fixed in ice-cold methanol or 4% paraformaldehyde (PFA), washed
401 in phosphate-buffered saline (PBS) and stored at 4°C. Parasites were detected using *P. vivax*-specific
402 antibodies (PvUIS4, PvBip and PvCSP) on methanol fixed cells as described in (Gural et al., 2018). For
403 IFITM3 staining, PFA-fixed cells were permeabilized with 0.2% TritonX100 for 10 minutes at room
404 temperature, washed in PBS and blocked with 2% bovine serum albumin (BSA) in PBS for 30 minutes at
405 room temperature. IFITM3 rabbit monoclonal antibody (59212, Cell Signaling) was incubated overnight at
406 4°C (1:100). Alexa-conjugated 488 secondary anti-rabbit antibody (1:1000) was incubated for 1 hour at
407 room temperature, followed by nuclear staining with Hoechst. Images were captured on a Nikon Eclipse Ti
408 or Zen-ApoTome inverted wide-field microscopes using 20x objectives. To quantify parasite size, the area
409 of parasite defined by the PvUIS4 staining was measured using NIS-Elements Microscope Imaging
410 Software and automatically converted to equivalent diameter.
411
412 **Fluorescence in situ hybridization**
413 *P. vivax*-infected MPCCs were fixed in 3.7% PFA for 10 minutes at room temperature, washed in PBS,
414 immersed in 70% ethanol and stored at 4°C. Custom labelled probes set specific to *Pv*18S rRNA (FAM
415 dye) and *PvGEXP5* (Quasar 670 dye) purchased from Stellaris were hybridized overnight in the dark at
416 37°C following the manufacturer's instructions. After nuclear staining and washing, cells were imaged in a
417 Nikon Eclipse Ti fluorescence microscope as described above.
418
419 **Sample Sizes and Statistical Analysis**
420 *n* represents the number wells from each plate as described in the figure legends. Exception for Figures 2C
421 and 2E, where *n* represents 2 independent infections. Methods used for computing statistical significance
422 are indicated in figure legends. Statistical significance was considered for p values below 0.05. Data was
423 analyzed using GraphPad Prism Software.
424

9

Bulk RNA-seq analysis

fastq files were mapped using STAR v. 2.5.3a (Dobin et al., 2013) against PVP01 *P. vivax* v1 genome assembly and annotation, and quantitated by RSEM v. 1.3.0 (Li and Dewey, 2011). Differential expression analysis was performed in DESeq2 on protein-coding genes (Love et al., 2014).

Tri-genome mapping target generation

Chromosomes and contigs from human (hg19), murine (mm10) [same ENSEMBL releases as in (Macosko et al., 2015)] and *P. vivax* genome (PvP01 v1 release) were renamed with a species-specific prefix and concatenated into a fasta file. Corresponding gtf files were adapted to match prefixed chromosome names, and genes names were adjusted as an ENSEMBLID_SPECIES_GeneSymbol concatenated string.

scRNA-seq processing

For each sample, fastq files originating from multiple sequencing runs were concatenated and processed using an analytical pipeline derived from the DropSeq pipeline v. 1.12, as described in (Gierahn et al., 2017) (https://github.com/broadinstitute/Drop-seq). Briefly, reads were converted to a bam file using picard v. 2.9.0-1-gf5b9f50-SNAPSHOT, tagged with cell and transcript barcodes, and subsequently sequencing adapters and polyadenosine tracts were trimmed. Upon regenerating fastq files, reads were aligned with STAR v. 2.5.3a (Dobin et al., 2013) against the aforementioned tri-genome reference. Genomic features of the aligned reads were annotated using the combined species-gene symbol nomenclature including gene and exon of origin when relevant. Bead synthesis errors were assessed and when possible, altered unique molecular identifiers (UMIs) were repaired. Cell barcode abundance was tallied, and gene expression was called for the top 10,000 cell barcodes. Count matrices of genes x cells were imported in the R v. 3.6 statistical environment and Seurat v.3 was used as the primary analytical package (Satija et al., 2015). Count matrices were merged into a single Seurat object, which was split by the sample of origin. Human, murine and *P. vivax* genes and transcripts counts were tallied for each cell barcode.

scRNA-seq analysis of human transcriptomes

Log10 ratios of human and murine-mapped transcripts per cell barcodes were calculated, and only cell barcodes with a ratio greater than 0 were retained. Dataset integration features were selected using Seurat's SelectIntegrationFeatures function, picking 3,000 genes and subsequently used to prepare the dataset for SCT-based integration PrepSCTIntegration). Integration anchors were identified using the FindIntegrationAnchor function, with parameters "SCT" as a normalization method, the aforementioned list of 3,000 genes as anchor features, 30 PCA dimensions, k.anchor=10 and using the first sample as reference (Butler et al., 2018). This integrated Seurat object was further filtered and cell barcodes displaying a human/murine coverage greater than 10-fold were retained for downstream analyses, resulting in 31,767 cells remaining. The integrated object was scaled and centered using a linear model, with scale.max=10, block.size =1,000 and min.cells.to.block=3,000. Principal component analysis was performed using RunPCA, retaining the top 30 components. The number of principal components retained was picked based on the inspection of the "elbow plot" and JackStraw procedure (n=100 replicates, 50 PCs) in Seurat. A UMAP embedding was calculated on the top 30 principal components using the RunUMAP function with flags n.neighbors=30, metric=cosine, learning.rate=1, min.dist=0.3, spread=1, set.op.mix.ratio=1, local.connectivity =1, repulsion.strength =1, negative.sample.rate=5, uwot.sgd= FALSE, seed.use : 42, angular.rp.forest : FALSE on the integrated object. Cluster identification was based on the Louvain algorithm for nearest-neighbor identification: the top 30 principal components were used to build the kNN graph, considering 20 nearest neighbors, with prune.snn=0.067, nn.method was an exact RANN (nn.eps=0) and Euclidean distance as the annoy. The resulting graph was partitioned using a shared nearest neighbor (SNN) modularity optimization-based clustering algorithm at resolution 0.8 to identify clusters (with 10 starts and 10 iterations, and standard modularity function). Gene and transcript coverage plots per cell barcodes were generated on the integrated dataset prior to the final filtering step (for barcodes

474   with a 10-fold enrichment for human transcript). Cluster markers were identified using the FindAllMarkers
475   function with logfc.threshold set to -100 and at least 10% of cells expressing the marker. Differential gene
476   expression signature was queried between *P. vivax*-positive and -negative cells using a Wilcoxon test
477   (implemented in the FindMarker function). Cell barcodes positive for eight or more parasite genes were
478   deemed to be *P. vivax*-positive.
479
480   **scRNA-seq analysis of *P. vivax* transcriptomes**
481   The Seq-Well analytical pipeline was run on the samples as described above. For samples for which pre-
482   and post-capture data were available, matching cell barcodes were identified in the corresponding genes x
483   cell matrices and UMI counts were summed over pre- and post-capture libraries. The resulting matrices
484   were merged into a Seurat object (2,171 cells, 85,276 genes). Only *P. vivax* genes were retained for
485   subsequent analysis (n=6,478). Samples which had less than 20 cells were excluded from the analysis. The
486   resulting object (n=1,991 cells) was split by dataset. Raw counts for each sample were exported into
487   individual text files and processed with Scanorama (v. 1.5, under Python 3.6 environment) for
488   normalization, batch correction and integration (Hie et al., 2019). The top 19 integration dimensions were
489   imported back into Seurat and used for data embedding using UMAP, as well as cluster elicitation via the
490   Louvain algorithm (similar to the procedure ran for the human compartment described above). Cluster-
491   specific gene markers were identified using a Wilcoxon test. Subclustering was performed by
492   extracting Scanorama dimensions for the cells of interest, followed by UMAP and Louvain-based cluster
493   identification. Heatmaps were generated in Seurat using hclust-based hierarchical clustering of the scaled
494   data with a centroid distance metric (UPMGC-equivalent), followed by manual editing.

495   REFERENCES
496
497   Adapa, S.R., Taylor, R.A., Wang, C., Thomson-luque, R., Johnson, L.R., and Jiang, R.H.Y. (2019).
498   Plasmodium vivax readiness to transmit : implication for malaria eradication. 1–12.
499
500   Babbitt, S.E., Altenhofen, L., Cobbold, S.A., Istvan, E.S., Fennell, C., Doerig, C., Llinas, M., and
501   Goldberg, D.E. (2012). Plasmodium falciparum responds to amino acid starvation by entering into a
502   hibernatory state. Proc. Natl. Acad. Sci. *109*, E3278–E3287.
503
504   Bennink, S., and Pradel, G. (2019). The molecular machinery of translational control in malaria parasites.
505   Mol. Microbiol. *112*, 1658–1673.
506
507   Boonhok, R., Rachaphaew, N., Duangmanee, A., Chobson, P., Pattaradilokrat, S., Utaisincharoen, P.,
508   Sattabongkot, J., and Ponpuak, M. (2016). LAP-like process as an immune mechanism downstream of IFN-
509   γ in control of the human malaria *Plasmodium vivax* liver stage. Proc. Natl. Acad. Sci. *113*, E3519–E3528.
510
511   Brancucci, N.M.B., Gerdt, J.P., Wang, C., De Niz, M., Philip, N., Adapa, S.R., Zhang, M., Hitz, E.,
512   Niederwieser, I., Boltryk, S.D., et al. (2017). Lysophosphatidylcholine Regulates Sexual Stage
513   Differentiation in the Human Malaria Parasite Plasmodium falciparum. Cell 1–13.
514
515   Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell
516   transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. *36*, 411–420.
517
518   Chen, A.X., Chhabra, A., Song, H.H.G., Fleming, H.E., Chen, C.S., and Bhatia, S.N. (2020). Controlled
519   Apoptosis of Stromal Cells to Engineer Human Microlivers. Adv. Funct. Mater. *30*, 1–10.
520
521   Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and
522   Gingeras, T.R. (2013). STAR: Ultrafast universal RNA-seq aligner. Bioinformatics *29*, 15–21.
523
524   Ferreira, A., Schofield, L., Enea, V., Schellekens, H., Meide, P. van der, Collins, W.E., Nussenzweig, R.S.,
525   and Nussenzweig, V. (1986). Inhibition of development of exoerythrocytic forms of malaria parasites by
526   gamma-interferon. Science (80-.).
527
528   Filarsky, M., Fraschka, S.A., Niederwieser, I., Brancucci, N.M.B., Carrington, E., Carrió, E., Moes, S.,
529   Jenoe, P., Bártfai, R., and Voss, T.S. (2018). R ES E A RC H. Science (80-.). 1–6.
530
531   Gierahn, T.M., Wadsworth, M.H., Hughes, T.K., Bryson, B.D., Butler, A., Satija, R., Fortune, S., Love,
532   J.C., and Shalek, A.K. (2017). Seq-Well: portable, low-cost RNA sequencing of single cells at high
533   throughput. Nat. Methods *14*, 395–398.
534
535   Gural, N., Mancio-Silva, L., Miller, A.B., Galstian, A., Butty, V.L., Levine, S.S., Patrapuvich, R., Desai,
536   S.P., Mikolajczak, S.A., Kappe, S.H.I., et al. (2018). In Vitro Culture, Drug Sensitivity, and Transcriptome
537   of Plasmodium Vivax Hypnozoites. Cell Host Microbe *23*, 395-406.e4.
538
539   Hie, B., Bryson, B., and Berger, B. (2019). Efficient integration of heterogeneous single-cell transcriptomes
540   using Scanorama. Nat. Biotechnol. *37*, 685–691.
541
542   Howick, V.M., Russell, A.J.C., Andrews, T., Heaton, H., Reid, A.J., Natarajan, K., Butungi, H., Metcalf,
543   T., Verzier, L.H., Rayner, J.C., et al. (2019). The malaria cell atlas: Single parasite transcriptomes across
544   the complete Plasmodium life cycle. Science (80-.). *365*.
545
546   Hughes, T.K., Wadsworth, M.H., Gierahn, T.M., Do, T., Weiss, D., Andrade, P.R., Ma, F., de Andrade
547   Silva, B.J., Shao, S., Tsoi, L.C., et al. (2020). Second-Strand Synthesis-Based Massively Parallel scRNA-
548   Seq Reveals Cellular States and Molecular Features of Human Inflammatory Skin Pathologies. Immunity
549   *53*, 878-894.e7.
550

Kafsack, B.F.C., Rovira-Graells, N., Clark, T.G., Bancells, C., Crowley, V.M., Campino, S.G., Williams, A.E., Drought, L.G., Kwiatkowski, D.P., Baker, D.A., et al. (2014). A transcriptional switch underlies commitment to sexual development in malaria parasites. Nature *507*, 248–252.

Kaushansky, A., Douglass, A.N., Arang, N., Vigdorovich, V., Dambrauskas, N., Kain, H.S., Austin, L.S., Sather, D.N., and Kappe, S.H.I. (2015). Malaria parasites target the hepatocyte receptor EphA2 for successful host infection. Science *350*, 1089–1092.

Kim, A., Popovici, J., Menard, D., and Serre, D. (2019). Plasmodium vivax transcriptomes reveal stage-specific chloroquine response and differential regulation of male and female gametocytes. Nat. Commun. 25–28.

Kotliar, D., Lin, A., Logue, J., Hughes, T., Khoury, N., Raju, S., Wadsworth, M., Chen, H., Kurtz, J., Dighero-Kemp, B., et al. (2020). Single-cell profiling of Ebola virus infection in vivo reveals viral and host transcriptional dynamics. 1–19.

Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 21–40.

Liehl, P., Zuzarte-Luís, V., Chan, J., Zillinger, T., Baptista, F., Carapau, D., Konert, M., Hanson, K.K., Carret, C., Lassnig, C., et al. (2013). Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat. Med. *20*, 47–53.

Liehl, P., Meireles, P., Albuquerque, I.S., Pinkevych, M., Baptista, F., Mota, M.M., Davenport, M.P., and Prudêncio, M. (2015). Innate immunity induced by Plasmodium liver infection inhibits malaria reinfections. Infect. Immun. *83*, 1172–1180.

Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. *15*, 1–21.

Luther, J., Khan, S., Gala, M.K., Kedrin, D., Sridharan, G., Goodman, R.P., Garber, J.J., Masia, R., Diagacomo, E., Adams, D., et al. (2020). Erratum: Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation (Proceedings of the National Academy of Sciences of the United States of America(2020)117(11667–11673)Doi: 10.1073/pnas.1911870117). Proc. Natl. Acad. Sci. U. S. A. *117*, 16704.

Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A.R., Kamitaki, N., Martersteck, E.M., et al. (2015). Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell *161*, 1202–1214.

March, S., Ramanan, V., Trehan, K., Ng, S., Galstian, A., Gural, N., Scull, M.A., Shlomai, A., Mota, M.M., Fleming, H.E., et al. (2015). Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. Nat. Protoc. *10*, 2027–2053.

Patel, S.J., King, K.R., Casali, M., and Yarmush, M.L. (2009). DNA-triggered innate immune responses are propagated by gap junction communication. Proc. Natl. Acad. Sci. U. S. A. *106*, 12867–12872.

Poran, A., Nötzel, C., Aly, O., Mencia-Trinchant, N., Harris, C.T., Guzman, M.L., Hassane, D.C., Elemento, O., and Kafsack, B.F.C. (2017). Single-cell RNA sequencing reveals a signature of sexual commitment in malaria parasites. Nature 1–22.

Real, E., Howick, V.M., Dahalan, F.A., Witmer, K., Cudini, J., Andradi-Brown, C., Blight, J., Davidson, M.S., Dogga, S.K., Reid, A.J., et al. (2021). A single-cell atlas of Plasmodium falciparum transmission through the mosquito. Nat. Commun. *12*, 1–13.

Roth, A., Maher, S.P., Conway, A.J., Ubalee, R., Chaumeau, V., Andolina, C., Kaba, S.A., Vantaux, A.,

607 Bakowski, M.A., Luque, R.T., et al. (2018). A comprehensive model for assessment of liver stage therapies
608 targeting Plasmodium vivax and Plasmodium falciparum. Nat. Commun.
609
610 Sà, J.M., Cannon, M. V., Caleon, R.L., Wellems, T.E., and Serre, D. (2020). Single-cell transcription
611 analysis of Plasmodium vivax blood-stage parasites identifies stage- And species-specific profiles of
612 expression. PLoS Biol. *18*, 1–27.
613
614 Satija, R., Farrell, J.A., Gennert, D., Schier, A.F., and Regev, A. (2015). Spatial reconstruction of single-
615 cell gene expression data. Nat. Biotechnol. *33*, 495–502.
616
617 Schafer, C., Kappe, H.I., Roobsoong, W., Kangwanrangsan, N., Bardelli, M., Rawlinson, T.A.,
618 Dambrauskas, N., Trakhimets, O., Parthiban, C., Goswami, D., et al. (2020). iScience A Humanized Mouse
619 Model for Plasmodium vivax to Test Interventions that Block Liver Stage to Blood Stage Transition and
620 Blood Stage Infection A Humanized Mouse Model for Plasmodium vivax to Test Interventions that Block
621 Liver Stage to Blood Stage.
622
623 Schneider, W.M., Chevillotte, M.D., and Rice, C.M. (2014). Interferon-stimulated genes: A complex web
624 of host defenses. Annu. Rev. Immunol. *32*, 513–545.
625
626 Sheahan, T., Imanaka, N., Marukian, S., Dorner, M., Liu, P., Ploss, A., and Rice, C.M. (2014). Interferon
627 lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host
628 Microbe *15*, 190–202.
629
630 Sinha, A., Hughes, K.R., Modrzynska, K.K., Otto, T.D., Pfander, C., Dickens, N.J., Religa, A.A., Bushell,
631 E., Graham, A.L., Cameron, R., et al. (2014). A cascade of DNA-binding proteins for sexual commitment
632 and development in Plasmodium. Nature *507*, 253–257.
633
634 Spence, J.S., He, R., Hoffmann, H.H., Das, T., Thinon, E., Rice, C.M., Peng, T., Chandran, K., and Hang,
635 H.C. (2019). IFITM3 directly engages and shuttles incoming virus particles to lysosomes. Nat. Chem. Biol.
636 *15*, 259–268.
637
638 Tibúrcio, M., Dixon, M.W.A., Looker, O., Younis, S.Y., Tilley, L., and Alano, P. (2015). Specific
639 expression and export of the Plasmodium falciparum Gametocyte EXported Protein-5 marks the
640 gametocyte ring stage. Malar. J. *14*, 1–12.
641
642 Walzer, K.A., Kubicki, D.M., Tang, X., and Chi, J.-T.A. (2018). Single-Cell Analysis Reveals Distinct
643 Gene Expression and Heterogeneity in Male and Female Plasmodium falciparum Gametocytes . MSphere
644 *3*, 1–18.
645

Figure 1. Single-cell profiling of *P. vivax* liver-stage infection. **A.** Illustration of *P. vivax* liver-stages (purple) maintained in micropatterned co-cultures (MPCC) of human hepatocytes (brown) and supportive mouse fibroblasts (blue). Cultures were dissociated with trypsin (top) or directly collected in bulk (bottom). Sample processing pipeline is shown for whole transcriptome (top) and targeted (middle) single-cell and targeted bulk RNA sequencing (bottom). **B.** Parasite size distribution and collection days. Day 14 and PiK4-treated samples are enriched in nonreplicative hypnozoites (parasites < 10 μm diameter). Each dot represents an individual parasite (n = 3-8 wells pooled from 2 independent infections). Quantification of parasite numbers given in **Figure S1A**. **C.** Scatterplots comparing the number of *P. vivax* genes (left) and transcripts (right) prior and post-capture with parasite-specific baits. Efficient depletion of host genes shown in **Figure S1B**. **D-E.** UMAP of 1,991 individual *P. vivax* parasites colored by sample identity (**D**) and parasite cluster type (**E**) using Scanorama. Heatmap showing cluster-specific marker genes provided in **Figure S2A**.

Figure 2. Characterization of *P. vivax* individual transcriptomes. **A.** Heatmap showing the expression of gametocyte-specific genes for each parasite cluster. 100 parasites are shown, except clusters Pv_C4 and Pv_C8 that contain fewer cells. Each bar represents a single parasite. **B.** Volcano plot comparing differential expression of day 5 and day 11 samples on targeted bulk RNA-seq. Parasite gametocyte gene markers highlighted. Red for gametocyte-genes described in (Sà et al., 2020). Black for genes validated in **C-E**. **C.** Relative expression of gametocyte markers by quantitative RT-PCR (mean ± SEM; *n* = 2 independent infections; *t*-test: *, *p* < 0.05; **, *p* < 0.01). **D.** RNA in situ hybridization of *P. vivax* parasites at day 10. *GEXP5* transcripts shown in red. Scale bars, 10 μm. Quantification of *GEXP5*-positive and -negative schizonts (mean ± SEM; *n* = 4 wells; *t*-test: ****, *p* < 0.0001). **E.** Relative expression of *GDV1, AP2-G* and *PVS16* by quantitative RT-PCR at early timepoints (mean ± SEM; *n* = 2 independent infections; 1-way ANOVA test: *, *p* < 0.05; **, *p* < 0.01). FC, fold chnage; *G27/25,* gametocyte antigen; *PVS16,* parasitophorous vacuole membrane protein S16; *GAMER,* gamete release protein; *GEXP5,* gametocyte exported protein 5; *GDV1,* gametocyte development 1; *AP2-G,* AP2 domain transcription factor regulator of gametocytogenesis.

Figure 3. Characterization of *P. vivax* mid-stage transcriptomes. **A-B.** UMAP of 713 *P. vivax* parasites (Pv_C2-C4 re-clustered) colored by sample identity (**A**) and parasite subcluster types (**B**). **C.** UMAP as in **A** highlighting expression levels of *LISP2*, *PUF1*, genes encoding peptidases (*SRAP1* and *PVP01_0916200 vivapain-2*) and ApiAP2s (*AP2-G* and *AP2-FG*). **D.** Heatmap showing expression of gametocyte-specific genes for each parasite subcluster. Gene list as in **Figure 2A**. Each bar represents a single parasite. Expression of gametocyte markers in Pi4K-treated samples is shown in **Figure S3A**. **E.** Treatment (days 0-8) of *P. vivax* infected cultures with protease inhibitor E64 (1 μM; mean ± SEM; n = 3-5 wells; t-test: *, $p < 0.05$). Parasite size distribution is given in **Figure S3B**. *LISP2*, liver-specific protein 2; *PUF1*, Pumilio RNA binding protein; *SRAP1*, sea star regeneration associated protease; *AP2-G*, transcription factor regulator of gametocytogenesis; *AP2-FG*, female gametocyte-specific transcriptional regulator.

Figure 4. Dual scRNA-seq analysis of *P. vivax* liver-stage infection. **A.** UMAP of 31,767 individual cells colored by cell type cluster using Seurat. Sample identity and cell composition within each human cluster are shown in **Figures S4A-B**. **B.** UMAP as in **A** highlighting the *P. vivax*-positive hepatocytes in red. GSEA analysis in **Figure S4C**. **C.** Waterfall plot comparing *P. vivax*-positive versus -negative in cluster H0 (adjusted *p* < 0.05). **D-E.** Volcano plots comparing differential expression of *P. vivax*-positive cells on day 11 and day 8 (**D**) and AP2-G positive and negative (**E**). **F.** Scatter plot showing higher interferon (IFN) response in *P. vivax*-negative cells (grey) across all clusters. *P. vivax*-positive hepatocytes are colored in red in **C-F**. **G.** Dot plot showing expression of IFN-related genes throughout infection time course in naïve unexposed (U), mock-exposed (M) and *P. vivax*-exposed (P) samples. **H.** UMAP as in **A** highlighting *IFI6* and *IFIT1* expression levels in U, M and P samples.

Figure 5. IFN responses in *P. vivax*-infected and bystander hepatocytes. **A.** Expression of IFITM3 protein (green) in *P. vivax*-infected cultures at day 10. Representative images of small (left) and large (right) parasites. Scale bars, 20 μm. **B.** Quantification of IFITM3 positive hepatocytes relative to the infected cell. **C.** IFN treatment (days 5-8) of *P. vivax* infected cultures. Bar plots show quantification of parasite numbers at day 8 (mean ± SEM; n = 5-6 wells pooled from 2 independent infections; 1-way ANOVA test: *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$; *ns*, not significant). Parasite size distribution is given in **Figure S5**.